Journal of Infectious Diseases & Therapy
Open Access

Short Communication

Carbapenem-Resistant Klebsiella Pneumoniae Osteomyelitis and Soft Tissue Infections: A Descriptive Case Series

Camila D Odio1, David van Duin2, Eric Cober2,3, Lucileia Teixeira-Johnson2,3, Steven Schmitt2,3 and Jorgelina de Sanctis4*
1Cleveland Clinic Lerner College of Medicine at Case Western Reserve University, Cleveland Clinic Foundation, Cleveland, OH, USA
2Division of Infectious Diseases, UNC School of Medicine, Chapel Hill, NC, USA
3Department of Infectious Diseases, Cleveland Clinic Foundation, Cleveland, OH, USA
4Division of Infectious Disease, Spectrum Health Medical Group, Grand Rapids, MI, USA
Corresponding Author :	Jorgelina De Sanctis MD, Department of Infectious Diseases Spectrum Health, 230 Michigan Ave, NE Grand Rapids, MI 49503, USA Tel: 616-633-1433 Fax: 616-391 8665 E-mail: Jorgelina.deSanctis@spectrumhealth.org
Received November 26, 2014; Accepted December 16, 2014; Published January 07, 2015
Citation: Odio CD, van Duin D, Cober E, Teixeira-Johnson L, Schmitt S, et al. (2015) Carbapenem-Resistant Klebsiella Pneumoniae Osteomyelitis and Soft Tissue Infections: A Descriptive Case Series. J Infect Dis Ther 3:200. doi: 10.4172/2332-0877.1000200
Copyright: © 2015 Odio CD, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at Pubmed Scholar Google

Antimicrobial therapies for Carbapenem-resistant Klebsiella pneumoniae (CR-KP) infections are limited. We examine the presentation of and response to therapy in CR-KP osteomyelitis and soft tissue infections. Tigecycline monotherapy cured mild infections; the addition of amikacin and colistimethate did not increase survival in dire cases. The 45% mortality rate underscores the gravity of these infections.

Keywords